Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 10/20 | 0.45 |
| ▸ | ACE | P12821 | 10/20 | 0.45 |
| ▸ | CPA1 | P15085 | 10/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 10/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12053134 | 1.00 | ITGB3 (0.46) | ITGB3ITGA2BMMEACECPA1 | |
| SCHEMBL2336902 | 0.92 | OPRK1 (0.44) | ITGB3ITGA2BMMEACECPA1 | |
| SCHEMBL9980756 | 0.83 | SLC7A5 (0.51) | ITGB3ITGA2BPPARGPOLBKMT2A | |
| SCHEMBL12035152 | 0.83 | POLB (0.42) | ITGB3ITGA2BPPARGPOLBKMT2A | |
| SCHEMBL20489338 | 0.83 | ITGB3 (0.57) | ITGB3ITGA2B | |
| SCHEMBL15303130 | 0.81 | ITGB3 (0.52) | ITGB3ITGA2BMMEACECPA1 | |
| SCHEMBL9337698 | 0.81 | ITGB3 (0.62) | ITGB3ITGA2BMMEACECPA1 | |
| SCHEMBL11183676 | 0.81 | ITGB3 (0.62) | ITGB3ITGA2BMMEACECPA1 | |
| SCHEMBL8477239 | 0.81 | ITGB3 (0.62) | ITGB3ITGA2BMMEACECPA1 | |
| SCHEMBL13385726 | 0.80 | CA2 (0.58) | ITGB3ITGA2BMMEACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940791-B2 | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements | SIGNATURE R&D HOLDINGS, LLC (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940791-B2 | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements | SIGNATURE R&D HOLDINGS, LLC (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140200256-A1 | Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements | SIGNATURE R&D HOLDINGS, LLC (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140200256-A1 | Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements | SIGNATURE R&D HOLDINGS, LLC (US) | 2014-07-17 | — | — | US | disclosed |
| US-20110312890-A1 | ACETYLATED AMINO ACIDS AS ANTI-PLATELET AGENTS, NUTRITIONAL AND VITAMIN SUPPLEMENTS | SIGNATURE R&D HOLDINGS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110275713-A1 | Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements | SIGNATURE R&D HOLDINGS, LLC (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275713-A1 | Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements | SIGNATURE R&D HOLDINGS, LLC (US) | 2011-11-10 | — | — | US | disclosed |
| US-8003683-B2 | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements | SIGNATURE R&D HOLDINGS, LLC (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003683-B2 | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements | SIGNATURE R&D HOLDINGS, LLC (US) | 2011-08-23 | — | — | US | disclosed |
| US-20070112060-A1 | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements | SIGNATURE R&D HOLDINGS, LLC | 2007-05-17 | — | — | US | disclosed |
| US-20070112060-A1 | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements | SIGNATURE R&D HOLDINGS, LLC | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200256-A1 | Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements | PLTP, GP6, PDGFA | ITGB3 45/4885ITGA2B 104/4885MME 2430/4885 |
| US-20110312890-A1 | ACETYLATED AMINO ACIDS AS ANTI-PLATELET AGENTS, NUTRITIONAL AND VITAMIN SUPPLEMENTS | PLTP, GP6, PDGFA | ITGB3 45/4885ITGA2B 104/4885MME 2430/4885 |
| US-20070112060-A1 | Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements | PLTP, GP6, PDGFA | ITGB3 45/4885ITGA2B 104/4885MME 2430/4885 |
| US-20110275713-A1 | Acetylated amino acids as Anti-platelet agents, Nutritional And Vitamin Supplements | PLTP, GP6, PDGFA | ITGB3 45/4885ITGA2B 104/4885MME 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.